Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

"Accentuate the negative, eliminate the positive": engineering allergy therapeutics to block allergic reactivity through negative signaling.

"Accentuate the negative, eliminate the positive": engineering allergy therapeutics to block allergic reactivity through negative signaling. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • "Accentuate the negative, eliminate the positive": engineering allergy therapeutics to block allergic reactivity through negative signaling. Abstract Text:

    andrew saxonAndrew Saxon,chris kepleyChris Kepley,ke zhangKe Zhang,

    By targeting the dominant-negative signaling receptor FcgammaRIIb expressed on proallergic cells, we have developed 2 novel platforms for the treatment of IgE-mediated allergic disease. First is a genetically engineered bifunctional human fusion protein GE2, which is comprised of the Fc portions of human IgE and IgG1 with an interposed flexible linker designed as a long-term parenteral allergen-nonspecific therapy. GE2 blocks the effector phase of the IgE response in vitro in mice and human subjects and in vivo in the skin and airway and systemically in mice and monkeys. Whether reactivity against human GE2 in human subjects will limit its applicability remains to be determined. The second platform is designed to provide a safer form of allergen-specific immunotherapy and consists of genetically engineered chimeric human Fcgamma-allergen proteins, with Fcgamma-Fel d 1 as the prototype. The allergen portion binds to specific IgE on FcepsilonRs, whereas the Fcgamma portion coaggregates inhibitory FcgammaRIIb and drives inhibition of allergic reactivity. Fcgamma-Fel d 1 blocked human mast cell Fel d 1-induced allergic reactivity in vitro and in vivo in murine models while functioning as an immunogen but not as an allergen.

    "Accentuate the negative, eliminate the positive": engineering allergy therapeutics to block allergic reactivity through negative signaling. Publishing Authors By Initials

    a saxonA Saxon,c kepleyC Kepley,k zhangK Zhang,

    For similar abstracts research abstracts see: abstracts research

    PUBMED ID PMID:

    MEDLINE DATE:

    "Accentuate the negative, eliminate the positive": engineering allergy therapeutics to block allergic reactivity through negative signaling. Journal Published:

    PUBLICATION TYPE: Research Support, Non-U.S. Gov

    Journal: The Journal of allergy and clinical immunology

    VOLUME: 121

    Page Numbers: 320-5

    Journal Abbreviation: J. Allergy Clin. Immunol.

    ISSN: 1097-6825

    DAY: 20

    MONTH: 12

    YEAR: 2007

    "Accentuate the negative, eliminate the positive": engineering allergy therapeutics to block allergic reactivity through negative signaling. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 1275002

    "Accentuate the negative, eliminate the positive": engineering allergy therapeutics to block allergic reactivity through negative signaling. Keywords Mesh Terms:

    KEYWORDS:

    MESH TERMS:

    Chemical & Substance for Abstract: "Accentuate the negative, eliminate the positive": engineering allergy therapeutics to block allergic reactivity through negative signaling. Information

    Substance Name:

    Registry Number:

    Grant and Affiliation Information for "Accentuate the negative, eliminate the positive": engineering allergy therapeutics to block allergic reactivity through negative signaling.

    AFFILIATION: Department of Medicine, University of California, Los Angeles, CA 90095-16908, USA. asaxon@mednet.ucla.edu

    Country: United States

    United States Research PublicationUnited States Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: J Allergy Clin Immunol

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    "Accentuate the negative, eliminate the positive": engineering allergy therapeutics to block allergic reactivity through negative signaling Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News